COMPANY

Neuron23

HQ: South San Francisco, CA source · neuron23.com ↗ · West Coast

Keywords: diagnostics neurology Parkinson Disease Idiopathic Parkinson Disease Parkinson Early Parkinson Disease NEU-411 NEU-627 NEU-111 NEU-723

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series D · $96.5M · announced Jun 24, 2025 Company release ↗
Source quote
- Jun 24, 2025 · Company release ↗
  “– Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the closing of a $96.5 million Series D financing round led by a healthcare investor”

Raises announced in these releases: $96.5M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Jun 24, 2025 Raise Series D · $96.5M source ↗
Jun 2, 2025 Trial start Phase 1: A Study to Assess NEU-627 in Healthy Participants source ↗
Jan 17, 2025 Trial start 2: A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease source ↗
Sep 17, 2024 Trial start Phase 1: A Study to Assess NEU-111 in Healthy Participants source ↗
May 13, 2023 Trial start Phase 1: A Study to Assess NEU-411 in Healthy Participants source ↗
Jan 30, 2023 Trial start Phase 1: A Study to Assess NEU-723 in Healthy Participants source ↗
Jun 28, 2021 Trial start —: A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease source ↗

2027-12 (ESTIMATED) · 2 · A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease · NCT06680830

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06680830	A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease	2	Recruiting	Jan 17, 2025	2027-12 (estimated)
NCT06900751	A Study to Assess NEU-627 in Healthy Participants	Phase 1	Completed	Jun 2, 2025	Oct 28, 2025 (actual)
NCT06500442	A Study to Assess NEU-111 in Healthy Participants	Phase 1	Completed	Sep 17, 2024	Feb 22, 2025 (actual)
NCT05755191	A Study to Assess NEU-411 in Healthy Participants	Phase 1	Completed	May 13, 2023	Jun 3, 2024 (actual)
NCT04893083	A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease	Not listed	Terminated	Jun 28, 2021	Jun 30, 2023 (actual)
NCT05633745	A Study to Assess NEU-723 in Healthy Participants	Phase 1	Terminated	Jan 30, 2023	Jun 30, 2023 (actual)